Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Eiger Biopharma (NQ: EIGR )

11.02 USD -0.84 (-7.08%)
Official Closing Price Updated: 6:03 PM EST, Jan 15, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All news about Eiger Biopharma

< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
Investors Snatch EIGR Even Cheaper Than Its Secondary Stock Offering
Looking back to 5 days ago, Eiger BioPharmaceuticals Inc (EIGR) priced a 4,500,000 share secondary stock offering at $11.00 per share. Buyers in that offering made a considerable investment into the... 
Tags Stocks
From Market News Video
54 Biggest Movers From Thursday
Gainers Mustang Bio, Inc. (NASDAQ: MBIO) shares climbed 112.03 percent to close at $5.64 on Thursday following news the New ... 
Tags PAGS MBRX CENX
From Benzinga
48 Stocks Moving In Thursday's Mid-Day Session
Gainers Mustang Bio, Inc. (NASDAQ: MBIO) shares jumped 135 percent to $6.25 following news the New England Journal of Medicine ... 
Tags News TCBI MAN
From Benzinga
Eiger BioPharmaceuticals (EIGR) Shares Cross Below 200 DMA
In trading on Thursday, shares of Eiger BioPharmaceuticals Inc (EIGR) crossed below their 200 day moving average of $12.00, changing hands as low as $10.94 per share. Eiger BioPharmaceuticals Inc... 
Tags Stocks
From Market News Video
Mid-Morning Market Update: Markets Mostly Lower; Honeywell Tops Q1 Estimates
Following the market opening Thursday, the Dow traded up 0.05 percent to 26461.62 while the NASDAQ declined 0.51 percent to 7,955.91. ... 
Tags News Global Benzinga
From Benzinga
31 Stocks Moving In Thursday's Pre-Market Session
Gainers Mustang Bio, Inc. (NASDAQ: MBIO) shares rose 192.5 percent to $7.78 in pre-market trading following news the New England ... 
Tags ALQA VNTR Losers
From Benzinga
The Daily Biotech Pulse: Hookipa To Debut, Mustang Bio Skyrockets, AngioDynamics Sheds Portfolio
Here's a roundup of top developments in the biotech space over the last 24 hours: No biotech stocks hit 52-week highs on ... 
Tags Earnings FBIO AIMT
From Benzinga
11 Stocks To Watch For April 18, 2019
Some of the stocks that may grab investor focus today are: Wall Street expects Honeywell International Inc. (NYSE: HON) to report ... 
Tags TEAM ISRG Stocks to Watch
From Benzinga
Eiger BioPharmaceuticals Announces Pricing of Public Offering of Common Stock
Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR) today announced the pricing of an underwritten public offering of 4,500,000 shares of its common stock at a price to the public of $11.00 per share. All of... 
From PR Newswire
Eiger BioPharmaceuticals Announces Proposed Public Offering of Common Stock
Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR) today announced that it has commenced an underwritten public offering of shares of its common stock. All of the shares to be sold in the offering are to be... 
From PR Newswire
Eiger BioPharmaceuticals Appoints Market Access, Public Policy Expert, and Biotech Veteran Amit K. Sachdev to Board of Directors
Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), focused on the development and commercialization of therapies for serious rare and ultra-rare diseases, announced today the appointment of Amit K.... 
From PR Newswire
The Daily Biotech Pulse: Merck's Keytruda Clinches Another FDA Win, KemPharm Close To NDA Filing For ADHD Drug
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting ... 
Tags Earnings VIVE EDAP
From Benzinga
Eiger Announces 36% Durable Virologic Response at 24 Weeks Post-Treatment with Peginterferon Lambda in Phase 2 LIMT HDV Study at The International Liver Congress™ 2019
- Improved Tolerability in HDV-infected Patients vs Historical Peginterferon Alfa 
From PR Newswire
The Daily Biotech Pulse: NASH Cheer For Intercept, Gilead Layoffs, BioDelivery Licenses Constipation Drug
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting ... 
Tags VKTX MRK XBI
From Benzinga
Research Report Identifies Aerojet Rocketdyne, Knight-Swift Transportation, Potbelly, Aqua Metals, OrthoPediatrics, and Eiger BioPharmaceuticals with Renewed Outlook — Fundamental Analysis, Calculatin
In new independent research reports released early this morning, Capital Review released its latest key findings for all current investors, traders, and shareholders of Aerojet Rocketdyne Holdings,... 
From GlobeNewswire News Releases
The Week Ahead In Biotech: Conferences, PDUFA Dates And Clinical Trial Readouts
Biotech stocks ended higher for the second straight week, with the presentations at the American Association of Cancer Research annual ... 
Tags ADMA News Benzinga
From Benzinga
Sum Up The Pieces: IBB Could Be Worth $142
Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and... 
Tags ETFs
From ETF Channel
Eiger BioPharmaceuticals to Participate in Conferences in April
Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today announced that management will... 
From PR Newswire
Eiger BioPharmaceuticals Announces Oral Presentation of Phase 2 PREVENT Study Results of Avexitide in Post-Bariatric Hypoglycemia at Endocrine Society Meeting (ENDO) 2019
- Statistically Significant Reduction in Hyperinsulinemic Hypoglycemia 
From PR Newswire
The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trials, Earnings And IPOs
Biotech stocks came under pressure lastweekdespite two FDA approvals coming through. The FDA approved SAGE Therapeutics Inc ... 
Tags FGEN KLDO CYCC
From Benzinga
Eiger BioPharmaceuticals Management Team to Present and Participate in China Healthcare Investment Conference 2019
Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today announced that David Cory,... 
From PR Newswire
Eiger BioPharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Business Update
- Began 2019 with $100.4 million in cash, cash equivalents & short-term investments 
From PR Newswire
Eiger Late-Breaker Oral Presentation of Peginterferon Lambda Phase 2 LIMT Study at The International Liver Congress™ 2019
- 36% Durable Virologic Response at 24 Weeks Post-Treatment 
From PR Newswire
Eiger BioPharmaceuticals Management Team to Present and Participate in Jefferies HBV Investor Summit
Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today announced that David Cory, President... 
From PR Newswire
Clinigen and Eiger BioPharmaceuticals Launch Worldwide Managed Access Program for Lonafarnib for Patients with Progeria and Progeroid Laminopathies
Clinigen Group plc (AIM:CLIN, ‘Clinigen’), the global pharmaceutical and services company, has partnered with Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR, ‘Eiger’) to launch a worldwide lonafarnib... 
From Business Wire News Releases
Eiger BioPharmaceuticals Announces the Appointment of Stephana Patton as General Counsel, Corporate Secretary, and Chief Compliance Officer
Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today announced the appointment of Dr.... 
From PR Newswire
Add Up The Parts: IBB Could Be Worth $145
Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and... 
Tags ETFs
From ETF Channel
Eiger BioPharmaceuticals Announces Patent Protection for Lonafarnib Boosted with Ritonavir for Treatment of Hepatitis Delta Virus Infection in Europe and Japan
Expanded Patent Portfolio Now Includes U.S., Europe and Japan 
From PR Newswire
Eiger BioPharmaceuticals Announces Oral Presentation of Phase 2 PREVENT Study of Avexitide in Post-Bariatric Hypoglycemia (PBH) at Upcoming Endocrine Society (ENDO) Meeting 2019 in New Orleans
Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), focused on the development and commercialization of targeted therapies for rare diseases, today announced an oral presentation has been granted for... 
From PR Newswire
EIGR Crosses Above Key Moving Average Level
In trading on Monday, shares of Eiger BioPharmaceuticals Inc (EIGR) crossed above their 200 day moving average of $11.28, changing hands as high as $12.07 per share. Eiger BioPharmaceuticals Inc shares... 
Tags Stocks
From Market News Video
< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.